EMA Authorised: Vaxneuvance (pneumococcal polysaccharide conjugate vaccine (adsorbed)) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorises Vaxneuvance (pneumococcal polysaccharide conjugate vaccine, adsorbed) for pneumococcal infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Vaxneuvance (pneumococcal polysaccharide conjugate vaccine (adsorbed))

Snippet

Status: Authorised. Therapeutic area: Pneumococcal Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 14/07/2026